Af­ter #ASH22: Post-mortem analy­sis on biggest Twit­ter buzz around drugs, stud­ies and bio­phar­mas

The Amer­i­can So­ci­ety of Hema­tol­ogy (ASH) con­fer­ence end­ed Tues­day and is the “most com­pre­hen­sive hema­tol­ogy event of the year,” so it’s no sur­prise that Twit­ter was abuzz with the hema­tol­ogy and blood can­cer re­search and drug news this week. But what got the biggest buzz? Glob­al­Da­ta’s post-mortem analy­sis broke out the lead­ing top­ics, themes and in­flu­encers from ASH on Twit­ter.

Among the top bio­phar­ma com­pa­nies trend­ing were blue­bird bio, Adap­tive Biotech, As­traZeneca and Ar­cel­lx. The cor­po­rate Twit­ter posts pro­mot­ed hema­tol­ogy and blood can­cer sci­ence com­mit­ments, and pre­sent­ed re­search or in­vit­ed at­ten­dees to stop by com­pa­ny booths for a vis­it.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN